Is Bio Techne Stock a Good Investment?
Bio Techne Investment Advice | TECH |
- Examine Bio Techne's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Bio Techne's leadership team and their track record. Good management can help Bio Techne navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Life Sciences Tools & Services space and any emerging trends that could impact Bio Techne's business and its evolving consumer preferences.
- Compare Bio Techne's performance and market position to its competitors. Analyze how Bio Techne is positioned in terms of product offerings, innovation, and market share.
- Check if Bio Techne pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Bio Techne's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Bio Techne Corp stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Bio Techne Corp is a good investment.
Sell | Buy |
Cautious Hold
Market Performance | Insignificant | Details | |
Volatility | Very steady | Details | |
Hype Condition | Low key | Details | |
Current Valuation | Undervalued | Details | |
Odds Of Distress | Very Low | Details | |
Economic Sensitivity | Responds to the market | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Strenth (F Score) | Frail | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unlikely Manipulator | Details |
Examine Bio Techne Stock
Researching Bio Techne's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.94. Bio Techne Corp last dividend was issued on the 19th of August 2024. The entity had 4:1 split on the 30th of November 2022.
To determine if Bio Techne is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Bio Techne's research are outlined below:
| Bio Techne Corp has a frail financial position based on the latest SEC disclosures | |
| Over 99.0% of the company shares are owned by institutional investors | |
| On 30th of August 2024 Bio Techne paid $ 0.08 per share dividend to its current shareholders | |
| Latest headline from express.co.uk: Reform UK celebrate huge poll victory - Labour and Tories should be very worried |
Bio Techne Quarterly Liabilities And Stockholders Equity |
|
Bio Techne uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Bio Techne Corp. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Bio Techne's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 1st of February 2024 Upcoming Quarterly Report | View | |
| 1st of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 13th of August 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 30th of June 2023 Last Financial Announcement | View |
Earnings surprises can significantly impact Bio Techne's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Bio Techne's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2006-01-31 | 2005-12-31 | 0.1 | 0.11 | 0.01 | 10 | ||
2005-10-27 | 2005-09-30 | 0.1 | 0.11 | 0.01 | 10 | ||
2004-08-10 | 2004-06-30 | 0.09 | 0.08 | -0.01 | 11 | ||
2004-04-27 | 2004-03-31 | 0.08 | 0.09 | 0.01 | 12 | ||
2004-01-27 | 2003-12-31 | 0.07 | 0.08 | 0.01 | 14 | ||
2003-10-23 | 2003-09-30 | 0.07 | 0.08 | 0.01 | 14 | ||
2003-08-12 | 2003-06-30 | 0.07 | 0.08 | 0.01 | 14 | ||
2003-05-01 | 2003-03-31 | 0.07 | 0.08 | 0.01 | 14 |
Know Bio Techne's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Bio Techne is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Bio Techne Corp backward and forwards among themselves. Bio Techne's institutional investor refers to the entity that pools money to purchase Bio Techne's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Mackenzie Investments | 2024-06-30 | 2.9 M | Mairs & Power Inc | 2024-06-30 | 2.7 M | Bank Of New York Mellon Corp | 2024-06-30 | 2.7 M | Champlain Investment Partners, Llc | 2024-06-30 | 2.7 M | Massachusetts Financial Services Company | 2024-06-30 | 2.6 M | Select Equity Group Lp | 2024-06-30 | 2.5 M | Macquarie Group Ltd | 2024-06-30 | 2.5 M | Brown Capital Management, Llc | 2024-06-30 | 2.4 M | Marshall Wace Asset Management Ltd | 2024-06-30 | 2 M | Vanguard Group Inc | 2024-06-30 | 18.2 M | Blackrock Inc | 2024-06-30 | 15 M |
Bio Techne's market capitalization trends
The company currently falls under 'Large-Cap' category with a current market capitalization of 12.28 B.Market Cap |
|
Bio Techne's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | 0.13 | 0.16 | |
| Return On Capital Employed | 0.10 | 0.09 | |
| Return On Assets | 0.06 | 0.06 | |
| Return On Equity | 0.08 | 0.08 |
Determining Bio Techne's profitability involves analyzing its financial statements and using various financial metrics to determine if Bio Techne is a good buy. For example, gross profit margin measures Bio Techne's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Bio Techne's profitability and make more informed investment decisions.
Bio Techne's Earnings Breakdown by Geography
Evaluate Bio Techne's management efficiency
Bio Techne Corp has return on total asset (ROA) of 0.0574 % which means that it generated a profit of $0.0574 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.0833 %, meaning that it created $0.0833 on every $100 dollars invested by stockholders. Bio Techne's management efficiency ratios could be used to measure how well Bio Techne manages its routine affairs as well as how well it operates its assets and liabilities. The Bio Techne's current Return On Tangible Assets is estimated to increase to 0.16, while Return On Capital Employed is projected to decrease to 0.09. As of now, Bio Techne's Other Current Assets are increasing as compared to previous years. The Bio Techne's current Total Current Assets is estimated to increase to about 648.3 M, while Other Assets are projected to decrease to under 8.8 M.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | 13.12 | 13.77 | |
| Tangible Book Value Per Share | 3.74 | 3.92 | |
| Enterprise Value Over EBITDA | 31.70 | 19.42 | |
| Price Book Value Ratio | 5.46 | 6.78 | |
| Enterprise Value Multiple | 31.70 | 19.42 | |
| Price Fair Value | 5.46 | 6.78 | |
| Enterprise Value | 2.2 B | 2.3 B |
The analysis of Bio Techne's management efficiency is an essential part of evaluating and assessing the financial and operational performance of the entity. It is also vital to analyze Bio Techne's future growth prospects and the overall market conditions to determine the value and potential of its stock. The analysis involves studying a range of financial metrics such as revenue, earnings, profit margins, cash flow, debt, market share, and external factors such as economic trends, industry outlook, competition, and government regulations. The goal of Bio Stock analysis is to determine whether it is undervalued, fairly valued, or overvalued and to make informed investment decisions.
Dividend Yield 0.0041 | Forward Dividend Yield 0.0041 | Forward Dividend Rate 0.32 | Beta 1.269 |
Basic technical analysis of Bio Stock
As of the 25th of September, Bio Techne shows the Mean Deviation of 1.63, downside deviation of 2.34, and Risk Adjusted Performance of 0.0428. In respect to fundamental indicators, the technical analysis model gives you tools to check existing technical drivers of Bio Techne, as well as the relationship between them.Bio Techne's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Bio Techne insiders, such as employees or executives, is commonly permitted as long as it does not rely on Bio Techne's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Bio Techne insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Kim Kelderman over two weeks ago Acquisition by Kim Kelderman of 1492 shares of Bio Techne at 66.97 subject to Rule 16b-3 | ||
Kim Kelderman over three weeks ago Acquisition by Kim Kelderman of 1492 shares of Bio Techne at 66.97 subject to Rule 16b-3 | ||
Klimovsky Judith V over three months ago Insider Trading | ||
Harold Wiens over six months ago Bio Techne exotic insider transaction detected | ||
Rupert Vessey over six months ago Acquisition by Rupert Vessey of 1625 shares of Bio Techne subject to Rule 16b-3 | ||
Harold Wiens over six months ago Bio Techne exotic insider transaction detected | ||
Harold Wiens over a year ago Bio Techne exotic insider transaction detected |
Bio Techne's Outstanding Corporate Bonds
Bio Techne issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Bio Techne Corp uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Bio bonds can be classified according to their maturity, which is the date when Bio Techne Corp has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| HSBC Holdings PLC Corp BondUS404280DR76 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View | |
| International Game Technology Corp BondUS460599AD57 | View | |
| BNP Paribas FRN Corp BondUSF1R15XK367 | View | |
| Morgan Stanley 3971 Corp BondUS61744YAL20 | View |
Understand Bio Techne's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Bio Techne's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.0428 | |||
| Market Risk Adjusted Performance | 0.0715 | |||
| Mean Deviation | 1.63 | |||
| Semi Deviation | 2.25 | |||
| Downside Deviation | 2.34 | |||
| Coefficient Of Variation | 2220.54 | |||
| Standard Deviation | 2.29 | |||
| Variance | 5.26 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (0.21) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0615 | |||
| Maximum Drawdown | 15.5 | |||
| Value At Risk | (3.05) | |||
| Potential Upside | 3.4 | |||
| Downside Variance | 5.47 | |||
| Semi Variance | 5.04 | |||
| Expected Short fall | (1.78) | |||
| Skewness | (0.72) | |||
| Kurtosis | 4.08 |
| Risk Adjusted Performance | 0.0428 | |||
| Market Risk Adjusted Performance | 0.0715 | |||
| Mean Deviation | 1.63 | |||
| Semi Deviation | 2.25 | |||
| Downside Deviation | 2.34 | |||
| Coefficient Of Variation | 2220.54 | |||
| Standard Deviation | 2.29 | |||
| Variance | 5.26 | |||
| Information Ratio | (0.01) | |||
| Jensen Alpha | (0.07) | |||
| Total Risk Alpha | (0.21) | |||
| Sortino Ratio | (0.01) | |||
| Treynor Ratio | 0.0615 | |||
| Maximum Drawdown | 15.5 | |||
| Value At Risk | (3.05) | |||
| Potential Upside | 3.4 | |||
| Downside Variance | 5.47 | |||
| Semi Variance | 5.04 | |||
| Expected Short fall | (1.78) | |||
| Skewness | (0.72) | |||
| Kurtosis | 4.08 |
Consider Bio Techne's intraday indicators
Bio Techne intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Bio Techne stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
| Accumulation Distribution | 23071.7 | |||
| Daily Balance Of Power | 0.0972 | |||
| Rate Of Daily Change | 1.0 | |||
| Day Median Price | 78.19 | |||
| Day Typical Price | 77.93 | |||
| Price Action Indicator | (0.66) | |||
| Period Momentum Indicator | 0.21 |
Bio Techne Corporate Filings
F4 | 16th of September 2024 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 12th of September 2024 Other Reports | ViewVerify | |
10K | 22nd of August 2024 Annual report required by the U.S. Securities and Exchange Commission (SEC) of a company financial performance | ViewVerify |
8K | 7th of August 2024 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
Bio Stock media impact
Far too much social signal, news, headlines, and media speculation about Bio Techne that are available to investors today. That information is available publicly through Bio media outlets and privately through word of mouth or via Bio internal channels. However, regardless of the origin, that massive amount of Bio data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Bio Techne news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Bio Techne relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Bio Techne's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Bio Techne alpha.
Bio Techne Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Bio Techne can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Bio Techne Corp Historical Investor Sentiment
Investor biases related to Bio Techne's public news can be used to forecast risks associated with an investment in Bio. The trend in average sentiment can be used to explain how an investor holding Bio can time the market purely based on public headlines and social activities around Bio Techne Corp. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Bio Techne's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Bio Techne and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Bio Techne news discussions. The higher the estimate score, the more favorable the investor's outlook on Bio Techne.
Bio Techne Maximum Pain Price across 2024-10-18 Option Contracts
Bio Techne's options can also be used to analyze investors' bias and current market sentiment in the context of behavioral finance. For example, Max pain usually refers to a trading concept that asserts that market manipulation can cause the market price of Bio Techne close to the expiration of its current option contract to expire worthlessly. According to most research, about 35% of options are not executed, with roughly 50% traded out before expiration. So, Max pain occurs when market makers reach a net favorable position across all options at a strike price where option holders stand to lose the most money. By contrast, option sellers may reap the most after selling more options than buying, causing them to expire worthlessly. Please continue to view the detailed analysis of Bio Techne's options.
Bio Techne Corporate Management
| Lynne Hohlfeld | Senior Division | Profile | |
| Luca Cicchetti | Managing Director | Profile | |
| Brenda JD | Gen VP | Profile | |
| Martin Wirtz | Senior Development | Profile | |
| Cheryl Bethune | Senior Officer | Profile | |
| Gerry Andros | Vice Marketing | Profile |
Additional Information and Resources on Investing in Bio Stock
When determining whether Bio Techne Corp offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Bio Techne's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Bio Techne Corp Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Bio Techne Corp Stock:Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Bio Techne Corp. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. You can also try the Share Portfolio module to track or share privately all of your investments from the convenience of any device.
Is Life Sciences Tools & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Bio Techne. If investors know Bio will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Bio Techne listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth (0.44) | Dividend Share 0.32 | Earnings Share 1.05 | Revenue Per Share 7.349 | Quarterly Revenue Growth 0.016 |
The market value of Bio Techne Corp is measured differently than its book value, which is the value of Bio that is recorded on the company's balance sheet. Investors also form their own opinion of Bio Techne's value that differs from its market value or its book value, called intrinsic value, which is Bio Techne's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Bio Techne's market value can be influenced by many factors that don't directly affect Bio Techne's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Bio Techne's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Bio Techne is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Bio Techne's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.